FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * CHALMERS DEREK T 2. Issuer Name and Ticker or Trading Symbol Cara Therapeutics, Inc. [ CARA ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)__X__ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
President & CEO
(Last)         (First)         (Middle)
C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM ST, 9TH FLOOR
3. Date of Earliest Transaction (MM/DD/YYYY)
12/30/2020
(Street)
STAMFORD, CT 06902
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  12/30/2020    S(1)    6078 (2) D $15.30  936593  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
(1)  This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting of the RSUs reported on Form 4 filed with the Securities and Exchange Commission on December 29, 2020, and does not represent a discretionary trade by the Reporting Person.
(2)  Represents the number of shares required to be sold by the Reporting Person to cover tax withholding as described in footnote (1).

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
CHALMERS DEREK T
C/O CARA THERAPEUTICS, INC.
4 STAMFORD PLAZA, 107 ELM ST, 9TH FLOOR
STAMFORD, CT 06902
X
President & CEO

Signatures
/s/Darren DeStefano, Attorney-in-Fact 12/30/2020
**Signature of Reporting Person Date
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Aug 2021 to Sep 2021 Click Here for more Cara Therapeutics Charts.
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Sep 2020 to Sep 2021 Click Here for more Cara Therapeutics Charts.